Information on the target
Sai Parenteral’s is a diversified pharmaceutical formulations company with integrated capabilities across research, development, and manufacturing. The company operates through two core verticals: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services. Its extensive product portfolio addresses multiple high-demand therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, dermatology, and vitamins, minerals, and supplements.
The company offers a wide range of dosage forms, such as injectables, tablets, capsules, liquid orals, ointments, and dry syrups, with a notable strength in sterile injectable manufacturing for critical care and penicillin-based therapies. Sai Parenteral operates five manufacturing facilities in India, boasting an aggregate installed capacity of 1,160 million units per annum, and is supported by multiple regulatory accreditations, including WHO-GMP, PIC/S, and TGA-Australia. The company has a presence in various markets, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
Industry overview in the target’s specific country
The pharmaceutical industry in India has experienced significant growth over the past few decades, driven by increasing healthcare needs, rising disposable incomes, and a growing population. India is recognized as one of the largest producers of generic drugs globally, contributing to a substantial portion of the world's pharmaceutical supply. The country's pharmaceutical market is projected to reach USD 65 billion by 2024, reflecting a compound annual growth rate (CAGR) of around 11-12%.
Moreover, the Indian government has been actively promoting the pharmaceutical sector through various initiatives, including the Production-Linked Incentive (PLI) scheme, which aims to boost domestic manufacturing and reduce dependency on imports. This supportive regulatory environment, combined with a robust talent pool in research and development, positions India as a favorable location for pharmaceutical companies looking to innovate and expand their operations.
In addition, the increasing prevalence of chronic diseases and the demand for advanced healthcare solutions are driving the growth of the pharmaceutical industry in India. The rise of telemedicine and digital health solutions has further accelerated the adoption of innovative therapies and drug delivery systems, creating new opportunities for pharmaceutical companies to enhance patient care and improve health outcomes.
As a result, the Indian pharmaceutical industry is not only poised for growth but also presents a competitive landscape for companies like Sai Parent…